Immunocore Holdings PLC (IMCR) ニュース

Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer

Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian...

Immunocore to present at the 2024 Cantor Global Healthcare Conference

Immunocore to present at the 2024 Cantor Global Healthcare Conference (OXFORDSHIRE, England &...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form 8-K - Current report

Immunocore announces transition of Chief Financial Officer

Immunocore announces transition of Chief Financial Officer (OXFORDSHIRE, England & CONSHOHOCKEN, Penn...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Immunocore reports second quarter financial results and provides a business update

KIMMTRAK® (tebentafusp-tebn) net revenues of $75.3 million in 2Q 2024 driven by US growth Registrational Phase...

Immunocore to report second quarter 2024 financial results and host call on August 8, 2024

Immunocore to report second quarter 2024 financial results and host call on August 8, 2024 (OXFORDSHIRE...

Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma

Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial...

Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response

Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor...

Form 8-K - Current report

Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024

Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in...

Immunocore to present at the Jefferies Global Healthcare Conference

Immunocore to present at the Jefferies Global Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN...

Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma

Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for...